Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Since trial evidence on methylphenidate is short-term and low-certainty, what improvements should we expect to see, and when would we reassess or stop if they don't appear?
Well-supported by good-quality research. how we score evidence
Caveat on this rating: 41% of included trials were industry-funded, and this review series' very-low-certainty GRADE ratings are disputed by many ADHD researchers who consider them overly conservative relative to clinical consensus.
Pooling 212 randomized trials with 16,302 children and adolescents, methylphenidate improved teacher-rated ADHD symptoms (SMD -0.74) and increased non-serious adverse events like sleep and appetite problems by about 23% without a detectable rise in serious harms, but the review rated the certainty of all of this evidence as very low.
Worth asking
Since trial evidence on methylphenidate is short-term and low-certainty, what improvements should we expect to see, and when would we reassess or stop if they don't appear?
What it is FDA approved for
Read off the label. Trial duration and approval year are shown only where they were recorded — never inferred.
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
Source
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) — Storebø OJ, et al. (2025)
Top-tier peer-reviewed journal
Read the source: https://doi.org/10.1002/14651858.CD009885.pub4
DOI: 10.1002/14651858.CD009885.pub4
How this was scored
- Study design
- Meta-analysis of randomised trials
- Funding
- Funding not disclosed
- Published in
- Top-tier peer-reviewed journal
- Sample size
- 16,302
- Preregistered
- Yes
- Conflicts disclosed
- Yes
- Independent of proponent
- not recorded
- Retracted
- No
Read the full scoring rubric, including what it can't tell you.
Published August 19, 2026.
Questions
How strong is the evidence behind this?
Resolv rates this source "strong evidence". Well-supported by good-quality research. It scores 83 out of 100 on our published rubric. One caveat travels with that badge: 41% of included trials were industry-funded, and this review series' very-low-certainty GRADE ratings are disputed by many ADHD researchers who consider them overly conservative relative to clinical consensus. The score is calculated from recorded facts about the source — study design, funding, publication venue, sample size, preregistration — not typed in by an editor.
What is the source for this?
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) — Storebø OJ, et al. (2025). Published in: Top-tier peer-reviewed journal. DOI: 10.1002/14651858.CD009885.pub4. The full source is linked on this page so you can read it yourself.
Who paid for this research, and does that matter?
Study design: Meta-analysis of randomised trials. Funding: Funding not disclosed. Independence from the proponent is not recorded. Industry sponsorship is one of the most reliably measured biases in medicine, which is why funding carries real weight in the score rather than sitting in a footnote.
Is methylphenidate (Ritalin, Concerta, Metadate, Daytrana, Quillivant, Jornay), ritalin, concerta, metadate, daytrana, quillivant, jornay FDA approved?
Yes — FDA approved for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy. Approval is for a specific indication, not for everything the drug is prescribed for.
Is this medical advice?
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.
This is information to bring to your prescriber, not medical advice and not a reason to change anything on your own. Nothing here is an instruction to stop or reduce a medication. If you are in crisis, call or text 988.